Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Summary

This phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules. Canakinumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving canakinumab may prevent the development of lung cancer.

Timeline

Start

2021-07-20

Primary completion

2027-12-31

Completion

2027-12-31

Drugs

Indications